Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts.
Kai ShaoXiaochen HuLuca KleineidamMelina StarkSlawek AltensteinHolger AmthauerHenning BoeckerRalph BuchertKatharina BuergerMichaela ButrynYanning CaiYue CaiNicoleta Carmen CosmaGuanqun ChenZhigeng ChenMarcel DaamenAlexander DrzezgaEmrah DüzelMarkus EsslerMichael EwersKlaus FliessbachFlorian C GaertnerWenzel GlanzTengfei GuoNiels HansenBeiqi HeDaniel JanowitzIngo KilimannBernd J KrauseGuoyu LanCatharina LangeChristoph LaskeYuxia LiRuixian LiLin LiuJie LuFansheng MengMatthias H MunkOliver PetersRobert PerneczkyJosef PrillerAlfredo RamirezBoris-Stephan RauchmannMatthias ReimoldAxel RomingerAyda RostamzadehNina Roy-KluthAnja SchneiderAnnika SpottkeEike Jakob SpruthPan SunStefan TeipelXiao WangMin WeiYongzhe WeiJens WiltfangShaozhen YanJie YangXianfeng YuMingkai ZhangLiang Zhangnull nullMichael WagnerFrank JessenYing HanElizabeth KuhnPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
SCD in amyloid-positive (Aβ+) participants predicts a steeper cognitive decline. This finding does not rely on specific SCD or amyloid operationalization. This finding is not specific to SCD patients recruited from memory clinics. This finding is valid in both German and Chinese populations. Aβ+ older adults with SCD could be a target population for interventional trials.